Objective
To develop a novel tool to increase the number of patients with prostate cancer eligible for active surveillance (AS) without increasing the risk of unfavourable pathological features (i.e., misclassification) at radical prostatectomy (RP).
Patients and Methods
Overall, 16 049 patients with low-or intermediate-risk prostate cancer treated with RP were identified. Misclassification was defined as non-organ confined or grade group ≥3 disease at RP. The coefficients of a logistic regression model predicting misclassification were used to develop a risk score. We then performed a systematic analysis of different thresholds to discriminate between patients with or without unfavourable disease and we compared it to available AS criteria.
Introduction
Active surveillance (AS) represents an increasingly used option that aims to delay or avoid active treatment in selected patients with localised prostate cancer [1] [2] [3] [4] . The oncological safety of this approach strongly depends on the adoption of strict selection criteria to identify eligible patients [5] . Although pathological findings at radical prostatectomy (RP) represent surrogate endpoints when developing selection approaches for AS candidates, several criteria that would allow for the reliable identification of insignificant prostate cancer that would pose little threat to patients, even if left untreated, have been proposed [3, 6] . These criteria are mainly based on clinical parameters such as PSA, clinical stage, and biopsy findings. Nonetheless, the risks of misclassification and adverse oncological outcomes during follow-up associated with their use are not negligible. For example, up to 25% of patients potentially eligible for AS would harbour a non-organ confined disease or primary Gleason pattern 4 at RP [7] [8] [9] [10] [11] [12] . These individuals, in turn, would be at increased risk of disease recurrence and mortality at long-term follow-up when included in AS protocols. Moreover, although the development of strict criteria based on predefined thresholds of different variables would facilitate their use in clinical practice, the lack of flexibility in these models might limit the number of patients with pathologically indolent prostate cancer potentially eligible for AS [8] , thus increasing the risk of overtreatment [13] .
We hypothesised that the development of a novel tool that would allow for the individual estimation of the risk of pathologically unfavourable disease at RP, a surrogate endpoint for stronger oncological outcomes in AS patients, might result in more potential AS candidates without compromising the oncological efficacy of this approach.
Patients and Methods

Study Population
After Institutional Review Board approval, 29 121 patients with prostate cancer treated with RP AE pelvic lymph node dissection between 2000 and 2016 at four tertiary referral centres (IRCCS Ospedale San Raffaele, Milan, Italy; CHU Mondor, Paris, France; Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Germany; and Netherlands Cancer Institute, Amsterdam, The Netherlands) were identified. Patients with missing preoperative and pathological data (n = 3969) and those with <8 cores taken at prostate biopsy (n = 5239) [1] 
Covariates and Endpoints
All patients included in the study underwent TRUS-guided biopsies performed by experienced urologists at high-volume. Clinical stage was obtained according to the DRE performed by the attending urologist. Prostate volume was measured by TRUS. Pathological specimens were processed by senior dedicated uropathologists. All included patients had complete clinical and pathological data. The TNM stage was applied according to the 2002 American Joint Committee on Cancer staging system for prostate cancer. Biopsy and pathological Gleason scores were categorised in five groups according to the ISUP 2014 consensus conference [14] . The grade group for patients diagnosed and treated before 2014 was retrospectively assigned. The outcome of the study was represented by the presence of unfavourable disease at final pathology, defined as non-organ confined disease and/or lymph node invasion (LNI) and/or pathological grade group ≥3. This represents a surrogate endpoint for stronger oncological outcomes in patients considered for inclusion in AS protocols [9] .
Statistical Analyses
The Mann-Whitney and chi-squared tests were used to compare differences in medians and proportions, respectively. Uni-and multivariable analyses assessed predictors of unfavourable disease. The covariates included in the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria (i.e., clinical stage, biopsy grade group, PSA level at diagnosis, the number of positive cores, and PSA density) were used. We then developed a novel risk score predicting unfavourable disease based on the coefficients derived from the logistic regression multivariable model. The discrimination accuracy of the model was quantified using the receiver operating characteristic (ROC)-derived area under the curve (AUC). The model was subjected to 2000 bootstrap resamples for reduction of overfit bias and for internal validation. The extent of over-or under-estimation of the histologically confirmed vs predicted unfavourable disease was graphically explored using a calibration plot. A decision-curve analysis (DCA) was used to determine the clinical net benefit associated with the use of the model [15] . We subsequently identified patients eligible for AS according to different AS criteria (namely, PRIAS [16] , Toronto [17] , University of California San Francisco (UCSF) [18] , and Royal Marsden [19] ) and we assessed the rate of unfavourable disease at final pathology. A systematic analysis of the ability of different clinical eligibility criteria to predict unfavourable disease was then performed, where we assessed the proportion of patients eligible for AS and the rate of unfavourable disease at final pathology. Finally, we performed a systematic analysis of different thresholds calculated using our novel risk score to discriminate between patients with or without unfavourable disease. In particular, we sought to identify a risk calculator threshold that would increase the number of patients potentially eligible for AS r-project.org). All tests were two-sided, with a statistical significance level set at P < 0.05.
Sensitivity Analyses
Our analyses were repeated in a sub-cohort of patients diagnosed after the year 2005 (n = 14 034) to account for potential effects of modifications in the grading system that occurred over time. Table 1 shows the clinical and pathological characteristics of the 16 049 patients included in the study. The median age at surgery was 64 years. Overall, 6933 (43.2%) and 9 116 (56.8%) patients had low-and intermediate-risk disease, respectively. Overall, 8659 (54.0%), 5249 (32.7%) and 2141 (13.3%) patients had biopsy grade group 1, 2 or 3, respectively. The median PSA level, PSA density and number of positive cores were 6.6, 0.15, and 3 ng/mL, respectively. Overall, 5289 (33.0%) patients had unfavourable disease characteristics at final pathology. When patients were stratified according to the presence of unfavourable disease, there were statistically significant differences for age, PSA level, number of positive cores, percentage of positive cores, biopsy grade group, and PSA density (all P < 0.001).
Results
Baseline Characteristics
Uni-and Multivariable Analyses
At univariable analyses, PSA level, clinical stage, biopsy grade group, the number of positive cores and PSA density were significantly associated with the risk of unfavourable disease at final pathology (Table 2 ; all P < 0.001). The same covariates represented independent predictors of unfavourable disease at multivariable analyses (all P < 0.001). A novel risk score based on the multivariable coefficients was then developed (Data S1). The coefficients are depicted in the  Table S1 . The bootstrap corrected AUC of this model at internal validation was 75.2% (95% CI 74.3-75.9%). The Figure S1 depicts the ROC curve of the risk score for unfavourable disease. The calibration plot of predicted probabilities vs actual rates of unfavourable disease characteristics indicated excellent concordance with a slight overestimation at predicted risks of <20% (Fig. 1) . The DCA demonstrated that the adoption of the novel risk score improved clinical risk prediction against threshold probabilities of unfavourable disease between 10% and 80% (Fig. 2) .
Systematic Analyses of Clinical Criteria and Risk Calculator-Derived Threshold to Predict Unfavourable Disease
Overall, 3303 (20.6%), 6933 (43.2%), 5200 (32.4%) and 7802 (51.4%) patients were eligible for AS according to the PRIAS, Toronto, UCSF and Royal Marsden criteria, respectively (Fig. 3) . The PRIAS criteria were associated with a lower rate of misclassification (13%) as compared to the other protocols (18%, 16.4% and 21.6% for Toronto, UCSF and Royal Marsden criteria, respectively). Moreover, the PRIAS criteria were associated with a lower rate of pT3b and/or grade group ≥4 and/or LNI as compared to other criteria. The subsequent analyses were therefore focused on how the PRIAS criteria could be modified in order to increase the number of patients potentially eligible for AS without increasing the risk of misclassification. Removing one of the PRIAS criteria would increase the proportion of patients potentially eligible for AS (Table 3 ). In particular, considering patients for AS regardless of initial PSA levels would slightly increase the proportion of eligible patients (from 20.6% to 22.5%) without increasing the rate of unfavourable disease. Nonetheless, removing other criteria resulted in a substantial increase in the risk of unfavourable disease. For example, the exclusion of the number of positive cores from the PRIAS criteria would result in 37% of patients being potentially eligible for AS with a rate of unfavourable disease of 15%. When considering the novel riskcalculator derived thresholds, the adoption of an 18% threshold would substantially increase the proportion of eligible patients from 20.6% to 29.4% without increasing the risk of unfavourable disease as compared to the PRIAS criteria. Moreover, the 18% threshold calculated using the novel tool would result into a lower proportion of patients with pT3b and/or grade group ≥4 and/or LNI as compared to the PRIAS criteria (1.6% vs 1.8%).
Sensitivity Analyses
At multivariable analyses, PSA level, clinical stage, biopsy grade group, the number of positive cores and PSA density were confirmed as independent predictors of unfavourable disease at final pathology (Table S2; 
Discussion
AS represents an increasingly adopted approach in selected patients with clinically localised prostate cancer [2] [3] [4] , wherẽ 65% of men included in an AS protocol are free from active treatment and <2% of them die from prostate cancer at 10 years [17] . Pathological findings at RP represent surrogate endpoints when considering the oncological safety of AS selection criteria. Nonetheless, the selection of AS candidates is currently based on parameters that should identify men with pathologically insignificant prostate cancer with a limited aggressiveness and a low risk of metastasis [3, 6] . Of note, currently available AS criteria are characterised by a misclassification rate of 15-30% [7] [8] [9] [10] [11] . At the same time, a non-negligible proportion of patients who would have been excluded from AS protocols according to current selection criteria harbour favourable disease characteristics at final pathology [8, 20] . There may be two main reasons for this. First, currently available criteria were initially developed to predict insignificant disease at RP in historic cohorts of patients [21] , whereas less stringent definitions of pathologically unfavourable disease have been proposed over the last few years [9, 20] . Second, they are based on predefined thresholds of different variables rather than on the individual risk estimation of unfavourable disease. For example, a patient might not be eligible for AS due to a single parameter that exceeds the predefined threshold even in the presence of a very favourable risk profile. Although this approach is easily applicable, it is characterised by a nonnegligible risk of over-treatment in a substantial proportion of patients. We therefore aimed to develop a novel tool that would allow individualised risk estimation of pathologically unfavourable disease amongst patients with low-or intermediate-risk prostate cancer in order to increase the proportion of patients potentially eligible for AS without increasing their risk of unfavourable disease.
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Our present results are several-fold. First, we developed a risk score based on clinical and biopsy information that reliably identified low-and intermediate-risk patients who were at increased risk of unfavourable disease at final pathology. This model achieved an AUC of 76% and showed excellent calibration characteristics at internal validation. Moreover, the adoption of the novel risk score improved clinical risk prediction against threshold probabilities of unfavourable disease between 10% and 80%. Although our model predicts a surrogate endpoint for stronger oncological outcomes, its implementation in clinical practice after external validation would allow for the identification of low-and intermediaterisk patients at increased risk of adverse pathological features who should not be considered for AS.
Second, we aimed at identifying a threshold value calculated using our risk score to detect patients at low-risk of unfavourable disease that should ideally be considered for inclusion in AS protocols. The use of arbitrary thresholds implies the acceptance of the possibility that a certain proportion of patients below that threshold would harbour unfavourable disease (i.e., non-organ confined disease and/or pathological grade group ≥3). Of note, the use of an 18% threshold resulted in a percentage of patients with unfavourable disease similar to that obtained using PRIAS criteria, which were associated with a lower risk of misclassification as compared to the Toronto, UCSF, and Royal Marsden criteria. Nonetheless, the use of an 18% threshold for AS selection would increase the proportion of patients potentially eligible by~50% as compared to the PRIAS criteria. The use of a risk calculator threshold rather than predetermined thresholds of clinical variables increased the proportion of men potentially eligible for AS without increasing the risk of pathologically unfavourable disease. For example, patients with grade group 2 disease should not be considered for AS according to the PRIAS criteria. However, an individual with cT1 grade group 2 prostate cancer, PSA level of 2 ng/mL, prostate volume of 80 mL and one positive core would have a risk of unfavourable disease similar to that observed in PRIAS candidates and, in turn, could be considered for AS. This is consistent with previous work showing that very selected patients with biopsy grade group 2 prostate cancer are not at increased risk of unfavourable disease as compared to their counterparts currently eligible for AS [10, 20] . Similarly, in the presence of low PSA levels and PSA density, patients with a grade group 1 prostate cancer and >2 positive cores could be considered candidates for AS without substantially increasing the risk of misclassification. Of note, a previous study failed to show an advantage in the use of the Kattan and Truong nomograms as compared to the PRIAS criteria in selecting patients with grade group ≤2 organ-confined prostate cancer [8] . However, both nomograms were initially developed to predict different outcomes (namely, organ confined cancer ≤0.5 mL without poorly differentiated elements and grade group ≥2, respectively) [22, 23] . This might explain the lack of benefit associated with their use in the AS setting as compared to the PRIAS selection criteria. On the other hand, we developed a risk score to predict misclassification according to a recently proposed definition based on the presence of grade group ≥3 and/or non-organ confined disease [9] .
From a clinical standpoint, the use of an 18% risk calculator threshold to select AS candidates would allow for a 50% increase in the number of patients eligible for AS without increasing the risk of unfavourable pathological characteristics. This would reduce the risk of over-treatment and treatment-related side-effects in patients with low-or intermediate-risk prostate cancer. Moreover, an increased use of AS in these patients would have a potential impact on healthcare expenditures, where it has been shown that AS allows for considerable cost savings over immediate treatment for patients with localised prostate cancer [24, 25] . It should also be noted that novel imaging modalities, such as multiparametric MRI (mpMRI), have been recently proposed to assist clinicians in AS selection [26] . Although some protocols have been modified to include mpMRI in the AS candidate selection process, further studies are needed to clarify its role [27] . For example, previous studies have suggested that patients eligible for AS according to the PRIAS criteria with visible lesions at mpMRI were more likely to experience upgrading at RP as compared to their counterparts with a negative mpMRI [28, 29] . On the other hand, other authors have failed to show an advantage associated with mpMRI-targeted biopsies as compared to the standard random approach in AS candidates [30] . Unfortunately, the evaluation of a large cohort of patients treated over a long period precluded us from comparing the accuracy of mpMRI and the novel risk calculator in predicting the risk of misclassification. Nonetheless, our risk calculator might 828 © 2018 The Authors BJU International © 2018 BJU International hypothetically be used to identify patients who would benefit from the use of mpMRI, whereas individuals with an upfront risk of misclassification higher than 18% according to clinical characteristics should not be considered for this imaging technique.
There are important limitations to our present data. First, the evaluation of a large cohort of patients undergoing RP and the use of a surrogate endpoint (namely, the risk of misclassification) limit the generalisability of our findings. Prospective investigations addressing the oncological safety of AS in patients with localised prostate cancer with a risk of misclassification of <18% according to our model are needed to validate of our findings. Second, although high-volume dedicated uropathologists performed the specimen assessment at tertiary referral centres, no centralised pathological review was performed. Moreover, due to the lack of data on the individual experience of the urologist performing the biopsy or the uropathologist assessing the specimen, we were not able to adjust our analyses for these variables. Finally, the lack of data on the percentage of cancer involvement in each core prevented us from testing AS criteria including this parameter. As such, we were not able to evaluate the characteristics of the Johns Hopkins criteria in our cohort [31] .
Conclusions
About 13% of patients potentially eligible for AS according to the PRIAS protocol undergoing RP will ultimately harbour unfavourable disease characteristics at final pathology. The use of a novel risk score for the selection of men who should be included in AS protocols would result in an absolute increase of~10% in the number of patients potentially eligible for this approach without increasing the risk of adverse pathological outcomes. 
Supporting Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . Receiver-operating characteristics (ROC) plot depicting the accuracy of the multivariable model predicting unfavourable disease at final pathology. Table S1 . Logistic regression coefficients predicting unfavourable disease at final pathology. Table S2 . Multivariable logistic regression analyses assessing predicting the presence of unfavourable disease at final pathology in 14 034 patients treated with radical prostatectomy (RP) at four tertiary referral centres. Data S1. Novel risk score predicting unfavourable disease based on the coefficients derived from the logistic regression multivariable model.
830
© 2018 The Authors BJU International © 2018 BJU International
